Insulet had its Relative Strength (RS) Rating upgraded from 88 to 91 Friday.
Here Are 3 Keys For Successful Stock Investing
This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history reveals that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves.
Insulet is building a consolidation with a 289.46 buy point. See if it can clear the breakout price in heavy trading.
The company reported -18% earnings growth in the latest quarterly report. Sales rose 17%. Keep an eye out for the company's next round of numbers on or around May 8.
Insulet earns the No. 5 rank among its peers in the Medical-Products industry group. Pro-Dex is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
